Physician

Pathology

Dr. Guilin Tang, MD

Guilin Tang works in the field of Pathology. She went to medical school at Baylor College of Medicine. Guilin Tang is also a published physician. She has 47 publication published. The most recent publication is: Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Dr. Guilin Tang accepts Medicare payments and is listed with Medicare.gov.

Publications

Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.
High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.
The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia.
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.
Prognostic Impact of Acquisition of Cytogenetic Abnormalities during the Course of Chronic Myelomonocytic Leukemia.
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.
Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant.
Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acut...
Lymphomatous variant of hairy cell leukaemia: a distinctive presentation mimicking low-grade B-cell lymphoma.
Chronic Myelomonocytic Leukemia with Nucleophosmin (NPM1) Mutation.
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.
Chronic lymphocytic leukemia with t(14;18)(q32;q21).
Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms.
MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Isolated +15 in bone marrow: Disease-associated or a benign finding?
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation.
Flow Cytometry Immunophenotypic Findings in Chronic Myelomonocytic Leukemia and Its Utility in Monitoring Treatment Response.
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AH...
Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Multi-color CD34(+) progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia.
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocyti...
High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes.
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification.
Chronic basophilic leukemia: a rare form of chronic myeloproliferative neoplasm.
Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification.
Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal ...
Diagnostic challenges related to myeloid/natural killer cells, a variant of myeloblasts.
The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis.
Blocking caspase-3-mediated proteolysis of IKKbeta suppresses TNF-alpha-induced apoptosis.
Inhibition of JNK activation through NF-kappaB target genes.
Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes.
Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review.
Homozygous inv(11)(q21q23) and MLL gene rearrangement in two patients with myeloid neoplasms.
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Doctors Specialties

Pathology

Accepted Insurances

Education

Baylor College of Medicine
University of Texas MD Anderson Cancer Center
University of Massachusetts
Hunan Medical University

Hospital

University of Texas M.D. Anderson Cancer Center

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1639224439
Last Name Of The Provider	TANG
First Name Of The Provider	GUILIN
View All

Similar Doctors

	Dr. Lizmarie Andino, MD This Doctor is OpenDoctor Recommended.
	Dr. Shylashree C. Chikkamuniyappa, MD This Doctor is OpenDoctor Recommended.
	Dr. Peggy B. Delahoussaye, MD This Doctor is OpenDoctor Recommended.
	Dr. Milton J. Finegold, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Nour Sneige, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert E. Jordan, MD
	Dr. Susan L. Haley, MD
	Dr. Megan G. Lockyer, DO
	Dr. Martha L. Mattioli, MD This Doctor is OpenDoctor Recommended.
	Dr. Kelly A. Khan, MD This Doctor is OpenDoctor Recommended.
	Dr. Asif Rashid, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael T. Tetzlaff, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Glenn D. Sandberg